

Oxford Technology 4 Venture Capital Trust Plc



UNAUDITED INTERIM REPORT

For the period 1 March 2021 to 28 February 2022

	Year Ended 28 February 2022	Year Ended 28 February 2021
Net Assets at Period End	£4.58m	£3.04m
Net Asset Value (NAV) Per Share	39.8p	26.4p
Dividend Paid in Period	-	5.0p
Cumulative Dividend Per Share	48.0p	48.0p
Total NAV Return Per Share	87.8p	74.4p
Share Price at Period End (Mid-Market)	25.0p	18.0p
Earnings Per Share	13.4p	(4.7)p

Company Number: 5038854

Registered Address: Magdalen Centre, Oxford Science Park, Oxford OX4 4GA

Statement on behalf of the Board

I would normally now be writing to fellow shareholders to present the Annual Report for the 12 months to 28 February 2022, but due to the proposed merger with the other three Oxford Technology VCTs (the “Merger”), our accounting period has been extended to 31 August 2022.

I am therefore pleased to provide rather than an Annual Report, an unaudited Interim Report for the 12 month period to 28 February 2022 which contains more details than our normal half year interim reports (particularly regarding the portfolio), but not as much about governance and other matters as would be included in an Annual Report. Apart from the usual portfolio update, I would like to draw your attention to two slightly more unusual matters in my report below, namely the Merger announcement and a change of auditor.

Overview

The unaudited Net Asset Value (NAV) per share has increased by 13.4p (50%) from 26.4p as at 28 February 2021 to 39.8p as at 28 February 2022. The increase is primarily due to an increase in the value of Arecor Therapeutics Plc (“Arecor”). Arecor floated on 3 June 2021 at a share price of 226p per share and the share price ended the period to 28 February 2022 at 350p per share. Further explanations are included in the portfolio review section below. Total Return since the Company’s launch is 87.8p per share. The Company paid no dividends during the year ended 28 February 2022 (2021: 5.0p). The cumulative dividends per share paid since inception in 2004 are 48.0p (2021: 48.0p).

Following the success of the recent share buyback offered to Oxford Technology 3 VCT plc shareholders, the Board is planning to offer a share buyback of up to 10% of its shares to OT4 shareholders in early June. Pricing is likely to be at a 10% discount to the prevailing NAV per share and the level of buyback will be determined by the liquidity of Arecor and its share price at the time of the buy back. This will allow OT4 shareholders to have an opportunity of an economic exit. Shareholders who wish to participate should take their own financial advice and if interested, register their interest with Chris Lloyd at Panmure Gordon (chris.lloyd@panmure.com).

Merger of the Oxford Technology VCTs

As announced on 4 March 2022, Oxford Technology VCT 4 plc (the “Company”, “OT4”) has entered discussions regarding a Merger of the Oxford Technology VCTs (“OT VCTs”) and a subsequent proposed move to a new investment manager, Edition Capital Investments Limited (“Edition”). The structure of the proposed Merger is designed to preserve the economic value of OT4’s portfolio for the benefit of the Company’s existing shareholders. Discussions are progressing and the proposed transaction, with full details, is expected to be formally announced in May.

Shareholders will be aware that as investments are realised, your Company reduces in size which means that your Company is now one of the smallest VCTs (as are each of the OT VCTs) in terms of NAV, market capitalisation and number of portfolio companies. The Boards of all four OT VCTs have previously stated that it would be preferable to have a larger asset base to share their operating costs due to the relentless upward trajectory of regulatory costs and the ongoing challenges of maintaining VCT status. The structure being proposed allows the shareholders of all four OT VCTs to benefit from the economies of scale of the Merger.

In addition, shareholders will be aware that for a number of years, your Directors have sought to find partners interested in using the existing VCT structure to launch their own share offering, and hence enabling one (or more) of the OT VCTs to expand its asset base. In Edition I believe we have found an ideal partner, especially in the light of our succession planning requirements: it has been clear for some years that OTM do not now consider VCTs a suitable vehicle for investing small sums in high risk reward start-ups, which is their area of interest and expertise. Having Edition as the new investment manager (raising new money in a separate share class) means longevity for the OT VCT portfolios such that the risk of ‘fire sale’ exits (due to these individual portfolios become sub-scale) is substantially reduced.

It is important to emphasise the point made above that the proposed Merger is designed to preserve the economic value of OT4’s portfolio for the benefit of existing shareholders as well as reducing its operating costs yet ensuring the portfolios of each of the OT VCTs remain ringfenced. By sharing the costs of the Merger with its sister VCTs as well as Edition, it has been possible to off-set the otherwise and hitherto prohibitive cost of combining the VCTs. Whilst the Board cannot be certain the proposals they are discussing will be finalised, good progress is being made with both Edition and the boards of the other OT VCTs, and I am optimistic a



OT4

Merger circular will be issued in May. I would therefore encourage all Shareholders to read the circular carefully when it is sent and to vote to support the various resolutions to enable the Merger to proceed (which will also be dependant on shareholders of Oxford Technology VCT 2 plc (“OT2”), the acquiring entity approving the Merger). The Board expects to offer shareholders an opportunity to question the Board via a Zoom webinar well ahead of the deadline for when voting closes. Shareholders should also note that whilst there will not be an Annual General Meeting in the summer as normal, there will be a shareholder meeting to approve the Merger which will provide an additional opportunity to question the Board.

Change to the Companies’ Auditor

UHY Hacker Young LLP (“UHY”) advised the Board that they wished to resign as auditor to the Company. UHY have taken the decision to withdraw from the VCT market following a change in its strategy over the sectors in which it operates. Accordingly, UHY has resigned as auditor to all of the OT VCT companies with effect from 23 February 2022. You will have already received the letter from UHY confirming that there are no matters connected with it ceasing to hold office that need to be brought to the attention of members or creditors of the Company for the purposes of section 519 of the Companies Act 2006. I would like to thank UHY for its services and support as external auditors.

The Directors have appointed Hazlewoods LLP (“Hazlewoods”) as OT4’s auditors. However, it is hoped that the proposed Merger will avoid the need for another audit for OT4 as a standalone entity.

Portfolio Review

OT4 has eight active companies in its portfolio, two of which are listed on the Alternative Investment Market (AIM) of the London Stock Exchange. No new investments were made in the period.

Your Company first invested in Arecor in July 2007. Since then, it has become a leader in innovative formulation technologies which allow pharmaceutical formulations to be stabilised in liquid form. The company has developed a successful fee for service and licencing business model as well as developing its own formulations for rapid action and highly concentrated insulin. Arecor floated on AIM on 3 June 2021 at a share price of 226p per share and now represents 63% of the Company’s NAV, trading at 390p per share as at 19 April 2022. Shares are currently subject to a lock in followed by an orderly market period, but the Directors are considering the most appropriate time to realise or partially realise the investment and return cash to shareholders. For each 10p change in Arecor, the current OT4 NAV moves by 0.7p. MirriAd Advertising plc is also listed on AIM.

STL Management Limited (“Select Technology”) distributes high quality document management software via its global channel partners. Over the last decade Select Technology has built up a global network of distributors and dealers through which it sells third party products targeted at its end customers’ scanning, copying and printing infrastructure. These products now include PaperCut, KPAX, Foldr, Drivve Image, EveryonePrint and Square 9 Enterprise Content Management.

Our valuation methodology for this investment is based on a sales multiple, and we have cautiously retained the discount that we have applied in recent years until we can fully assess the impact of various geopolitical events on Select Technology’s markets. However, the company itself is now seeing a recovery in trading conditions – this is welcome news after the turmoil of 2020 and the disruption in early 2021. OT4 received a small dividend from Select Technology in February 2022, possibly (and hopefully) a sign that normal trading is in the process of being resumed. As at 28 February 2022, OT4’s stake in Select Technology constituted just over 15% of the Company’s NAV. At the end of August 2021, Alex Starling joined the board of Select Technology to represent the OT VCTs’ interests as we seek to maximise shareholder value.

Diamond Hard Surfaces Limited (“DHS”) continues to sell its diamond like coating services to a range of customers whilst looking to the product opportunity which will allow it to scale. The business is stable and valued on a multiple of turnover. DHS represented 3.5% of NAV as at 28 February 2022.

As was reported in the half year accounts, the decision was made to move the core technology of Immunobiology Ltd (“ImmBio”) to Liverpool University to reduce costs whilst the technology transfer to ImmBio’s licensee China National Biotech Group continues. Since the move, Liverpool University has won a grant to lay the foundations for a challenge/carriage study to determine the extent to which pneumococcus is carried in the nose of vaccinated people.



OT4

The first grant finishes in April 2022 and could lead to a second grant to perform the study. Interest in whole cell vaccines has been limited during the Covid crisis, with the focus on synthetic vaccines which could be rapidly developed, tested and deployed. However, in recent months the interest in such vaccines has waned, as can be seen by the share price drops of companies involved in their development. It can be hoped that interest will now switch back to vaccines with the potential for a much wider immune response, and therefore ImmBio may be able to re-engage with additional potential partners. ImmBio represents 3.9% of NAV.

As at 28 February 2022, the two largest portfolio companies, Arecor and Select Technology, together accounted for just over 78% of NAV.

Adjusting for the latest quoted share prices (Arecor 390p and Mirriad 25p), and the running costs since 28 February 2022, the unaudited NAV per share has increased to 42.3p as of 19 April 2022. The valuations of the unquoted investments remain unchanged.

The Directors, along with the Investment Adviser, continue to take an active interest in the companies within the portfolio, supporting management teams (where possible) to achieve company development, but also to prepare companies for realisation at the appropriate time. It should however be noted that approaches do occur at other times, and the ability of the Directors and Investment Adviser to be able to provide support when such approaches occur is essential for maximising value.

Further details are contained within the Investment Manager's Report, and on our website at <https://www.oxfordtechnologyvct.com/vct4.html>.

VCT Qualifying Status

The Board continues to monitor all the VCT requirements very carefully in order to ensure that all the various qualifying tests are met and that qualifying investments comfortably exceed the current minimum threshold of 80% which is required for the Company to continue to benefit from VCT tax status. As at 28 February 2022, the HMRC value of qualifying investments of our portfolio was 81.0% (2021: 83.7%).

Liquidity

The issue of liquidity of unquoted companies within investment funds has remained a national topic of discussion this year. Shareholders may be interested to know that at the year-end over 70% of the Company's portfolio was held in cash or quoted AIM shares, thus providing short-term liquidity (though shareholders should note that stocks quoted on AIM may have limited liquidity at times).

Risk Factors

The geopolitical situation is distressing, and our thoughts go out to those who are affected by military actions and other violence. Whilst your Company's portfolio has no major direct contact with defence spending, there remains the possibility that any shift of government focus towards additional defence spending may have a long term impact on other areas of spending. The long term impact of sanctions is unclear, but it is hoped given the nature of the portfolio that they should not have a major impact on performance.

For much of the post 2008 era, inflation has been tamed by various mechanisms such as quantitative easing. Recent developments indicate that such efforts to 'kick the can down the road' may be coming to an end. Inflation is now forecast to hit high single figures – it is unclear to what extent the UK and the wider world economy is in a fit state to thrive in such a challenging environment.

Thankfully OT4's portfolio – despite being concentrated in only having 8 companies in it – is suitably diverse so as to provide a degree of protection from some of these global headwinds.

Dividends/Return of Capital

No dividend was paid or declared during the financial year.

Due to its relatively small size the Company remains exposed to balancing solvency requirements and compliance with VCT rules: there is no flexibility in the latter, and there is now much greater emphasis on Directors explaining to shareholders why it is still reasonable to adopt the going concern basis when accounts are being prepared.



OT4

Sufficient comfort regarding liquidity is provided by your Company's stakes in two AIM-listed companies. As mentioned in my introduction, expanding the size of the Company should further help improve this situation. The ongoing strategy remains to seek to crystallise value from the portfolio and distribute cash to shareholders.

Our priority is to maximise shareholder value and liquidity over the medium term by seeking exits for these holdings at the appropriate time, but remaining mindful of the need to meet both VCT qualifying and going concern tests.

Presentation of Interim Report

In order to reduce the length of this report, we have omitted details of the Company's objectives and investment strategy, its Advisers and Registrar and how to buy and sell shares in the Company. These details are all included in the Annual Reports, which together with previous half-yearly reports, are available for viewing on the Oxford Technology website.

VCT Market Changes

During the period under review, there have been no further amendments to the rules governing VCTs. The Chancellor of the Exchequer's Spring Statement was also subsequently delivered on 23 March 2022 and did not propose any changes to the legislation governing VCTs.

Cost Control

Your Board continues to look at methods of improving operational efficiency, reducing costs and, more generally putting in place appropriate plans to ensure that your VCT's operational costs relative to its overall size remain within acceptable limits. Over the last 5 years we have renegotiated almost every element of cost. Our investment management and Directors' fees and auditors' remuneration are amongst the lowest in the VCT industry. The largest remaining elements of cost are the LSE listing fee at more than £10k and the FCA fee of £6k. These regulatory fees seem to have relentless increases and bear disproportionately on a small company. Filed company accounts now also need to be produced in XHTML format, at additional cost, to comply with the first phase of mandatory electronic format reporting under FCA's Disclosure Guidance and Transparency Rules.

As mentioned in the introduction (assuming the Board puts forward the Merger recommendation it is currently envisaging, and shareholders of both the Company and OT2 approve the relevant resolutions), these annual costs will be able to be shared more widely in the future.

Environmental, Social and Governance (ESG)

Whilst many of the requirements under company law to detail ESG matters are not directly applicable to the Company, the Board is conscious of its potential impact on the environment as well as its social and corporate governance responsibilities.

Furthermore, the Investment Adviser takes ESG considerations into account when investing. The FCA reporting requirements consistent with the Task Force on Climate-related Financial Disclosures that commenced this year do not currently apply to the Company. However, it will be kept under review in light of any recommended changes.

Fraud Warnings – Boiler Room Fraud

We are aware of a number of cases where shareholders are being fraudulently contacted or are being subjected to attempts of identity fraud. Shareholders should remain vigilant of all potential financial scams or attempts for them to disclose personal data for fraudulent gains. The Board strongly recommends shareholders take time to read the Company's fraud warning section, including details of who to contact, contained within the Information for shareholders section of the Annual Reports from previous years.

Outlook and Prospects

This not being an accounting period year end statement, there is no AGM to look forward to. However, there will be a General Meeting following the expected publication in May of the Circular for the proposed Merger, and I look forward to speaking to you there, or in advance of that date if you have any questions about the proposals by contacting vcts@oxfordtechnology.com.



OT4

Given the Directors' view of the potential of the underlying assets, we continue to view the future with confidence. Assuming the Board put forward the resolutions they anticipate – and shareholders approve them – it will mean the end of OT4 as the holding vehicle for your investment, but this will continue to be maintained within a separate pool of assets within OT2 and at a lower holding cost.

One of those cost savings is that my chairmanship will be surplus to requirements, though I shall be staying on post-Merger as a director of the enlarged company for at least a year for continuity and to help prioritise the maximisation of shareholder value for holders of the OT4 share class.

I would therefore like to take this opportunity to thank my fellow shareholders, likely for the final time in a chairman's statement for Oxford Technology 4 VCT Plc for their continued support.

All the very best for the future.

David Livesley
Chairman
21 April 2022

Investment Manager's Review

OT4 was formed in 2004 and has invested in 35 companies which were start-up or early stage technology companies. Some of these companies failed with the loss of the investment. Some have succeeded and have been sold. The table shows the 10 companies remaining in the portfolio, 8 of which are active. A more detailed analysis is given of the major remaining investments on the following pages. Several still have the potential to deliver significant returns, most notably Arecor Therapeutics and Select Technology. OTM continues to help and advise the portfolio companies as they navigate these post pandemic times.

Updates on the largest four companies of the portfolio companies are contained in this report.

New Investments in the 12 month period.

There were no new investments during the 12 month period.

Disposals During the 12 month period.

Plasma Antennas was dissolved during the 12 month period but not before the outstanding loan was repaid to OT4 at a small increase to its previous carrying value. Metal Nanopowders and Superhard Materials were dissolved during the period. Oxis Energy went into administration in May 2021 but OT4 was already carrying this investment at a zero value.

Valuation Methodology

Quoted and unquoted investments are valued in accordance with current industry guidelines that are compliant with International Private Equity and Venture Capital (IPEVC) Valuation Guidelines and current financial reporting standards.

VCT Compliance

Compliance with the main VCT regulations as at 28 February 2022 and for the 12 month period then ended is summarised as follows:

Type of Investment By HMRC Valuation Rules	Actual	Target
VCT Qualifying Investments	81.0%	Minimum obligation of: 80%
Non-Qualifying Investments	19.0%	Maximum allowed: 20%
Total	100%	100%

The value used in the qualifying tests is not necessarily the original investment cost due to the complex rules required by HMRC, therefore the allocation of Qualifying investments as defined by the legislation can be different to the portfolio weighting as measured by market value relative to the net assets of the VCT.

At least 70% of each investment must be in eligible shares – Complied.

No more than 15% of the income from shares and securities is retained – Complied.

No investment constitutes more than 15% of the Company's portfolio (by value at time of investment or when the holding is added to) – Complied.

The Company's income in the period has been derived wholly or mainly (70% plus) from shares or securities – Complied.

No investment made by the VCT has caused the company to receive more than £5m of State Aid investment (£10 million for Knowledge Intensive Companies) in any rolling 12 month period and £12 million of state aid investment (£20 million for Knowledge Intensive Companies) during its lifetime – Complied as no new investments made.

Investment Portfolio as at 28 February 2022

Company	Description	Net Cost of investment £'000	Carrying value at 28/02/22 £'000	Change in value for the year £'000	% Equity held OT4	% Equity held All OTVCTs	% Net Assets
Arecor (bid price 350p)	Protein stabilisation	590	2,885	1,597	3.0	5.7	63.0
Select STL Management	Specialist photocopier interfaces	237	707	90	18.4	58.6	15.4
ImmBio	Novel vaccines	857	178	-	13.0	22.6	3.9
Diamond Hard Surfaces	Diamond coatings	640	160	(99)	49.9	49.9	3.5
Dynamic Extractions	Separation technology	377	114	30	30.4	30.4	2.5
Insense	Active wound healing dressings	476	67	-	2.1	5.6	1.5
Novacta	Antibiotics Development	347	59	-	2.3	2.3	1.3
MirriAd Advertising (bid price 18p)	Virtual product placement	-	9	(16)	0.0	0.0	0.2
Dynamic Discovery	E-mail archiving	-	-	-	5.6	5.6	-
Oxis Energy	Battery technology	305	-	-	0.2	0.3	-
Total Investments		3,828	4,179	1,602			91.3
Other Net Assets			399				8.7
Net Assets			4,578				100.0

	First Investment	Net Cost	Carrying Value 28/02/2022	Change in Value for the Year	% Equity Held
Arecor	July 2007	£590,196	£2,885,568	£1,596,681	3.0%

Arecor Therapeutics Plc is a leader in the development of innovative formulation technology that enables differentiated biopharmaceutical products. It has developed a proprietary, patent backed formulation technology platform that has been proven to stabilize a broad range of molecules as aqueous compositions. Many proteins, peptides and vaccines are too unstable in liquid form and/or at high concentrations to develop stable ready-to-use drugs and Arecor has overcome these challenges to significantly enhance the delivery of therapeutic medicines to patients. Arecor has continued the development of a portfolio of differentiated peptides through to clinical proof of concept, with an initial focus on diabetes as a therapeutic area.

The Company's original investment was in Arecor Ltd which became Arecor Therapeutics Plc when it floated on AIM on 3 June 2021, raising £20m at a share price of 226p. Since then its share price has risen to a peak of 460p and ended the year at 350p. Thus far it has been very thinly traded with the highest daily volume of just over 200,000 shares achieved when Arecor announced positive results for their AT278 ultra concentrated ultrarapid acting insulin. They have also announced that AT247 has progressed into Phase 1.

Since inception in 2007, Arecor has built a successful revenue generating business employing this technology to enable and differentiate biopharmaceuticals for a large cross section of the major pharmaceutical companies on a fee for service plus licensing model. Since floating, Arecor has announced 4 new collaborations.

The bid price as at 28 February 2022 used for this Arecor valuation was 350p per share.

Select – STL Management Ltd

www.selectec.co.uk

	First Investment	Net Cost	Carrying Value 28/02/2022	Change in Value for the Year	% Equity Held
Select - STL Management Ltd	August 2006	£236,703	£706,693	£89,943	18.4%

Select Technology (100% owned by STL Management Ltd) distributes high quality document management software via its global channel partners while adding significant further value through its development team by providing integrations or bespoke solutions. Select Technology grew significantly between 2010 and 2018 by focusing on print management software. Realising that this type of software was becoming increasingly commoditised, the company changed its focus to document capture and sharing, acquiring distribution rights to additional software solutions and introducing them to the market in an innovative way.

Covid-19 caused major disruption both to Select and to everyone in the industry globally. The biggest and most obvious change was that almost everyone was working from home which meant that all the long established procedures for managing and printing documents were disrupted. Another effect is that there were many consolidations/mergers globally, with larger companies acquiring smaller companies with the objective of reducing costs while increasing sales. Although print management remains a significant part of Select Technology's business, it has made a conscious effort to seek out and acquire regional rights to innovative document management systems which are appropriate to the new 'work-at-home' reality.

Among these products, for example are Foldr and Square9. Foldr was originally developed for teachers in schools. It enabled teachers to store and retrieve materials for their lessons, to write reports for their students and email these securely to the parents, with controls to ensure that the right report went to the right parent, but which also enabled all the reports to be sent to the school's central administration. Documents could be protected with various levels of security with different people being given different levels of access. Foldr has turned out to be very useful for businesses to manage their documents in a secure manner and even more so now that working from home is the norm. The level of security on a home laptop is generally less than was the case for the head-office security systems. Square9 is an Enterprise Content Management System. It is appropriate for the largest companies with thousands of employees and enables companies to store, find, access and manage documents and other information easily and securely and in compliance with GDPR and other security protocols.

Select Technology's sales grew from £210k in the year to 31 July 2010 to £5m in the year to 31 July 2021 and, despite the restrictions caused by the pandemic, the company still recorded a profit of £95k for the year. Subsequently, in the first half of the current financial year, the period August 2021 to January 2022, the company has reported turnover of £2.9m with a profit of £145k, the latter a result of measures to increase gross margin.

Select Technology is valued at a multiple of sales with a discount.

	First Investment	Net Cost	Carrying Value 28/02/2022	Change in Value for the Year	% Equity Held
ImmBio	October 2005	£856,601	£177,778	-	13.0%

ImmBio was founded in 1999 by Camilo Colaco to develop vaccines that engage dendritic cells. Dr. Colaco identified the role that Heat Shock Proteins play in activating the immune system. The company has programmes developing vaccines against Tuberculosis, Meningitis and Pneumonia. The TB and Meningitis vaccines have been partnered for development in China and India. ImmBio makes up 3.9% of the NAV of OT4.

Whilst ImmBio has not managed to find a pharmaceutical partner or acquirer during the year it has teamed up with Liverpool School of Tropical Medicine, who have applied for a grant to progress the programme to a challenge model of the protein based vaccine. They have won a first grant which is to validate the models they would use in the main study. A successful challenge study would address many of the questions potential partners have raised. Whether that would then result in them taking action is a separate question.

Progress with China National Biotech Group for its pneumococcal vaccine PnuBioVax has been slow, in part due to the pandemic. Further milestones payments will be made when the transfer of certain technology is complete.

The company is valued to reflect its stage of technical and commercial development and taking into account the preference cascade, but the outcome is likely to be quite binary.

Diamond Hard Surfaces
www.diamondhardsurfaces.com

	First Investment	Net Cost	Carrying Value 28/02/2022	Change in Value for the Year	% Equity Held
DHS	January 2005	£640,224	£159,627	(£99,268)	49.9%

Diamond Hard Surfaces Ltd (DHS), (3.5% of NAV) has developed an ultra-hard diamond-like coating which provides unusual properties to coated objects, including very high wear resistance and the ability to spread heat more evenly. Whilst the coating has attracted interest from a wide variety of companies, DHS has traditionally been unable to convert sampling activity into volume orders. A more recent focus on using the coating as a heat sink has attracted interest and DHS has grown sales to £320k for the year to December 2021 with an encouraging start to 2022.

DHS is valued using a sales multiple.



Lucius Cary
Director – OT4 Managers Ltd
Investment Manager
21 April 2022

Responsibility Statement of the Directors in respect of the interim report

We confirm that to the best of our knowledge:

- the 12 months' financial statements have been prepared in accordance with the statement "Interim Financial Reporting" issued by the Financial Reporting Council;
- the 12 months' report includes a fair review of the information required by law and regulations, being:
 - an indication of the important events that have occurred during the 12 month period and their impact on the condensed set of financial statements.
 - a description of related party transactions that have taken place in the 12 month period that may have materially affected the financial position or performance of the Company during that period and any changes in the related party transactions described in the last annual report that could do so.
- The assets of the Company include a cash balance of £403,000 and shares in two AIM quoted companies, one of which is quite liquid and readily accessible. After reviewing the forecast for the Company, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. The Company therefore continues to adopt the going concern basis in preparing these interim accounts.

On behalf of the Board:

David Livesley
Chairman
21 April 2022

Income Statement

	12 months to 28 February 2022			Year to 28 February 2021		
	Revenue	Capital	Total	Revenue	Capital	Total
	£'000	£'000	£'000	£'000	£'000	£'000
Gains on disposal of fixed asset investments	-	11	11	-	210	210
Unrealised gain/(loss) on valuation of fixed asset investments	-	1,602	1,602	-	(640)	(640)
Investment income	11	-	11	-	-	-
Investment management fees	(30)	-	(30)	(42)	-	(42)
Other expenses	(60)	-	(60)	(61)	-	(61)
Return on ordinary activities before tax	(79)	1,613	1,534	(103)	(430)	(533)
Taxation on ordinary activities	-	-	-	-	-	-
Return on ordinary activities after tax	(79)	1,613	1,534	(103)	(430)	(533)
Earnings per share – basic and diluted	(0.6)p	14.0p	13.4p	(0.9)p	(3.8)p	(4.7)p

There was no other Comprehensive Income recognised during the year.

The 'Total' column of the Income Statement is the Profit and Loss Account of the Company, the supplementary Revenue and Capital return columns have been prepared under guidance published by the Association of Investment Companies.

All Revenue and Capital items in the above statement derive from continuing operations.

The Company has only one class of business and derives its income from investments made in shares and securities and from bank and money market funds.

Balance Sheet

	As at 28 February 2022		As at 28 February 2021	
	£'000	£'000	£'000	£'000
Fixed asset investments at fair value		4,179		2,629
Debtors	11		1	
Cash at Bank	403		434	
Creditors: Amounts falling due within one year	(15)		(20)	
Net current assets		399		415
Net assets		4,578		3,044
Called up share capital		115		1,152
Capital redemption reserve		1,037		-
Share premium reserve		813		813
Unrealised capital reserve		656		(1,240)
Profit and Loss account		1,957		2,319
Total equity shareholders' funds		4,578		3,044
Net asset value per share		39.8p		26.4p

Statement of Changes in Equity

	Share Capital £'000	Capital Redemption Reserve £'000	Share Premium Reserve £'000	Unrealised Capital Reserve £'000	Profit & Loss Account £'000	Total £'000
As at 1 March 2020	1,152	-	813	(770)	2,958	4,153
Revenue return on ordinary activities after tax	-	-	-	-	(103)	(103)
Current period gains on disposal	-	-	-	-	210	210
Current period losses on fair value of investments	-	-	-	(640)	-	(640)
Prior years' unrealised gains now realised	-	-	-	(550)	550	-
Permanent diminution in value now realise	-	-	-	720	(720)	-
Dividends paid	-	-	-	-	(576)	(576)
Balance as at 28 February 2021	1,152	-	813	(1,240)	2,319	3,044
As at 1 March 2021	1,152	-	813	(1,240)	2,319	3,044
Revenue return on ordinary activities after tax	-	-	-	-	(79)	(79)
Current period gains on disposal	-	-	-	-	11	11
Current period gains on fair value of investments	-	-	-	1,602	-	1,602
Prior years' unrealised gains now realised	-	-	-	(11)	11	-
Permanent diminution in value now realised	-	-	-	305	(305)	-
Share capital reclassification	(1,037)	1,037	-	-	-	-
Balance as at 28 February 2022	115	1,037	813	656	1,957	4,578

Statement of Cash Flows

	12 months to 28 February 2022 £'000	Year to 28 February 2021 £'000
Cash flows from operating activities		
Return on ordinary activities before tax	1,534	(533)
Adjustments for:		
Gain on disposal of fixed asset investments	(11)	(210)
(Gain)/loss on valuation of fixed asset investments	(1,602)	640
(Decrease)/increase in creditors	(5)	10
(Increase)/decrease in debtors	(10)	9
Outflow from operating activities	(94)	(84)
Cash flows from investing activities		
Purchase of fixed asset investments	-	-
Sale of fixed asset investments	63	832
Inflow from investing activities	63	832
Cash flows from financing activities		
Dividends paid	-	(576)
Outflow from financing activities	-	(576)
(Decrease)/increase in cash and cash equivalents	(31)	172
Opening cash and cash equivalents	434	262
Closing cash and cash equivalents	403	434

Notes to the Report

1. Basis of preparation

The unaudited interim results which cover the 12 months to 28 February 2022 have been prepared in accordance with the Financial Reporting Council's (FRC) Financial Reporting Standard 104 Interim Financial Reporting ('FRS 104') and the Statement of Recommended Practice (SORP) 'Financial Statements of Investment Trust Companies and Venture Capital Trusts (revised 2021)'. Details of the accounting policies and valuation methodologies are included in the 2021 Annual Report.

2. Publication of non-statutory accounts

The unaudited interim results for the 12 months to 28 February 2022 do not constitute statutory accounts within the meaning of Section 415 of the Companies Act 2006. The comparative figures for the year ended 28 February 2021 have been extracted from the audited financial statements for that year, which have been delivered to the Registrar of Companies. The independent auditor's report on those financial statements, in accordance with chapter 3, part 16 of the Companies Act 2006, was unqualified. This interim report has not been reviewed by the Company's auditor.

3. Earnings per share

The calculation of earnings per share for the period is based on the return attributable to shareholders divided by the weighted average number of shares in issue during the period. There are no potentially dilutive capital instruments in issue and, therefore, no diluted returns per share figures are relevant.

4. Net asset value per share

The net asset value per share is based on the net assets at the period end divided by the number of shares in issue at that date (11,516,946 in each case).

5. Share Capital – Sub-division and Reclassification, and Reduction of Capital

As referred to in the Chairman's statement, each ordinary share of 10p in the capital of the Company was sub-divided and reclassified into one ordinary share of 1p and one deferred share of 9p, and then all of the deferred shares were repurchased and cancelled for the aggregate sum of 1p. The Company now has 11,516,946 ordinary shares of 1p each (and no deferred shares of 9p each).

6. Principal risks and uncertainties

The Company's assets consist of equity and fixed interest investments, cash and liquid resources. Its principal risks are therefore market risk, credit risk and liquidity risk. Other risks faced by the Company include economic, loss of approval as a Venture Capital Trust, investment and strategic, regulatory, reputational, operational and financial risks. These risks, and the way in which they are managed, are described in more detail in the Company's Annual Report and Accounts for the year ended 28 February 2021. The Company's principal risks and uncertainties have not changed materially since the date of that report although the impact of the military invasion of Ukraine by Russian forces may have a consequential impact on economic conditions globally. These may have an indirect impact on businesses in which the Company has invested, hindering growth, financing, or operations. Similarly, the threat of rising inflation may impact on the performance/profitability of our investees. Consequently, any change of governmental, economic, fiscal, monetary or political policy, and in particular any spending cuts or material increases in interest rates could affect, directly or indirectly, the performance of the Company (as a result of the performance of its underlying investments) and hence the value of, and returns from, the Company's shares.

7. Related party transactions

OT4 Managers Ltd, a wholly owned subsidiary, provides investment management services to the Company for a fee of 1% of net assets per annum. For operational reasons, OT4 made a short term interest free loan of £50k to Oxford Technology VCT Plc under the Common Payments and Liquidity agreement held between the VCTs during the period. The loan was repaid to OT4 before the year end.

Copies of this statement are available from Oxford Technology Management, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA and on the Company's website.

Company Information – Directors and Advisers

Board of Directors

David Livesley (Chairman)
Robin Goodfellow
David Livesley
Richard Roth

Accountants

Wenn Townsend
30 St Giles
Oxford OX1 3LE

Investment Manager & Registered Office

OT4 Managers Ltd
Magdalen Centre
Oxford Science Park
Oxford OX4 4GA
Tel: 01865 784466

Independent Auditor

Hazlewoods LLP
Staverton Court
Staverton
Cheltenham
GL51 0UX

Company Secretary

James Gordon
Gordons Partnership LLP
22 Great James Street
London WC1N 3ES

Registrars

Neville Registrars
Neville House
Steelpark Road
Halesowen B62 8HD
Tel: 0121 585 1131

Investment Adviser

Oxford Technology Management
Tel: 01865 784466
Email : vcts@oxfordtechnology.com

Bankers

Natwest Bank
121 High Street
Oxford OX1 4DD

Legal Entity Identifier

21380009M2EQZD452H80

Legal Adviser

Hill Dickinson LLP
50 Fountain Street
Manchester M2 2AS

Company Registration Number

5038854

Website

www.oxfordtechnologyvct.com/vct4.html

